Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keystone Nano Inc.

This article was originally published in Start Up

Executive Summary

Keystone Nano thinks its expertise in nanotechnology can be leveraged to achieve two valuable commercial goals: improving drug delivery and enhancing medical imaging. The company's Molecular Dots are particles that are just 20-30 nanometers wide and resist clumping. As such, they appear to be able to move through the body without disturbing the immune system.

You may also be interested in...

Is the FDA Ready for the Nanotechnology Revolution?

The burgeoning field of nanotechnology is creating hope as well as anxiety in the healthcare industry as researchers look for the best way to use the technology and the FDA grapples to create a policy for regulating products that incorporate the futuristic micro-miniature science. In health care, early focus has been on infection control products.

What Nanotech Means to Health Care Investors

If there's a common theme being articulated by CEOs of nanobiotechnology start-ups, it's that, at least financially, life has been difficult because they're early stage. Indeed, the nanotech label is less significant to health care investors than considerations related to their business strategy. Drug-delivery-oriented nanobiotechs, for example, must be strongly product focused to avoid the implications that they have an old, low-value model.

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts